Immunome

Historical price data

Immunome is a clinical-stage biotech focused on developing first-in-class and best-in-class targeted oncology therapies, with a core competency in antibody-drug conjugates (ADCs). Founded in 2023 via the merger of Immunome and Morphimmune under Dr. Clay Siegall's leadership, the company has rapidly built a multi-asset pipeline anchored by a late-stage gamma secretase inhibitor (varegacestat) and novel ADCs. Its strategy leverages deep ADC development expertise to systematically optimize novel agents, pursue strategic acquisitions, and address significant unmet needs in solid tumors.

A holistic, data-driven platform for the systematic optimization of antibody-drug conjugates (ADCs), focusing on novel target selection and the integrated engineering of antibody, linker, and payload components to maximize therapeutic index.